A Single-patient Study of Repeat-dose Administration of ProMetic Plasminogen (Human) Intravenous Infusion in an Adult With Hypoplasminogenemia

Prometic Biotherapeutics, Inc.0 个研究点开始时间: 2017年8月29日最近更新: 2020年4月24日

适应症

试验速览

阶段: 不适用
状态: No Longer Available
发起方: Prometic Biotherapeutics, Inc.

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

These are single-patient studies with repeat-dose administration of ProMetic Plasminogen IV infusion in one adult and one child with hypoplasminogenemia. These patients are under treatment to address wound healing and obstructions.

研究设计

研究类型: Expanded Access

入排标准

年龄范围: 16 Months 至 —（Child, Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Patient has provided informed consent.
•Patient has a diagnosis of compound homozygous Type 1 plasminogen deficiency as evidence by ligneous conjunctivitis since birth as well as involvement of the conjunctiva, nasopharynx, gingiva, tracheobronchial tree, gastrointestinal tract, and urinary tract.

排除标准

•Not applicable

研究者

发起方

Prometic Biotherapeutics, Inc.

申办方类型

Industry

责任方

Sponsor

相似试验

已完成

1 期

Multiple Dose Pharmacokinetics of Intranasal KetamineHealthy

NCT00519987Javelin Pharmaceuticals18

已完成

4 期

Efficacy and Safety of Palonosetron Hydrochloride in the Prevention of Nausea and VomitingNeoplasmsChemotherapy-Induced Nausea and Vomiting

NCT01481831Shanghai Changzheng Hospital599

已完成

1 期

To Evaluate the Pharmacokinetics and Safety/Tolerability of Lacosamide in 3 Dosages in Healthy Male Korean SubjectsEpilepsy

NCT01450111UCB Pharma51

已完成

1 期

Trial to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine in Healthy Korean SubjectsParkinson's Disease

NCT01964573UCB Pharma48

已完成

1 期

A Study to Investigate the Safety and Tolerability of Single and Repeat Doses of PC786Respiratory Syncytial Virus (RSV)

NCT03236233Pulmocide Ltd39